Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim BiotechCHIX:DIMP 82 Debt-to-Equity is 0.57 as of Jun. 2026, which is 46% above its 10-year median of 0.39. GuruFocus rates CHIX:DIMP with a GF Score™ of 82/100 and a GF Value™ of €221.02 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 72.06% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sartorius Stedim Biotech's Debt-to-Equity or its related term are showing as below:
CHIX:DIMp'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.39 Max: 1.46
Current: 0.57
During the past 13 years, the highest Debt-to-Equity Ratio of Sartorius Stedim Biotech was 1.46. The lowest was 0.10. And the median was 0.39.
CHIX:DIMp's Debt-to-Equity is ranked worse than 72.06% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs CHIX:DIMp: 0.57
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sartorius Stedim Biotech Debt-to-Equity Related Terms
Sartorius Stedim Biotech Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a Debt-to-Equity of 0.57 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sartorius Stedim Biotech and its competitors. This is 46% above median its historical median of 0.39. Over the past decade, Sartorius Stedim Biotech's Debt-to-Equity has ranged from 0.10 to 1.46. According to the industry distribution chart, Sartorius Stedim Biotech ranks #508 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 72.1%.
Is Sartorius Stedim Biotech's Debt-to-Equity too high?
Sartorius Stedim Biotech's current Debt-to-Equity of 0.57 is 46% above median its 10-year median of 0.39. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 1.46. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Sartorius Stedim Biotech's value of 0.57 is 147.8% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #508 out of 705 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #508 out of 705 companies for Debt-to-Equity. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Sartorius Stedim Biotech's value of 0.57 is 147.8% above this benchmark. Historically, Sartorius Stedim Biotech's own Debt-to-Equity has ranged from 0.10 to 1.46 over the past decade. While the company's 10-year median is 0.39 vs. the industry median of 0.23, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Debt-to-Equity of 0.57 is 147.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Debt-to-Equity is 0.57, which is 46% above median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €221.02, compared to a current price of €187.40 — trading 15.2% below its estimated fair value. The current Debt-to-Equity is 0.57, which is 46% above median its 10-year median of 0.39 and 147.8% above the Medical Devices & Instruments industry median of 0.23. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Debt-to-Equity is 0.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €187.40 is trading 15.2% below its estimated GF Value™ of €221.02.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
Debt-to-Equity: 0.57 (46% above median its 10-year median of 0.39)
GF Value™: €221.02 vs. price of €187.40 (15.2% below fair value)
Industry Position: 147.8% above the Medical Devices & Instruments median (#508 of 705)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for CHIX:DIMP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
